

GOSLING *et al.*  
Application No.: 09/686,020  
Page 4

PATENT

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
SLA:dmw

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph beginning at line 25 of page 2 has been amended as follows:

In a related aspect, the invention provides an isolated polynucleotide that encodes, or is complementary to a sequence that encodes, the CCX CKR polypeptide. In some embodiments the polynucleotide has at least 10, 15, 25, 50 or 100 contiguous bases identical or exactly complementary to SEQ ID NO:1. In various embodiments, the polynucleotide is the full-length sequence of SEQ ID NO:1, encodes a CCX CKR polypeptide of the invention (e.g., having the sequence of SEQ ID NO:2 ~~SEQ ID:2~~ or a fragment thereof), or selectively hybridizes under high stringent hybridization conditions to a polynucleotide sequence of SEQ ID NO:1. The polynucleotide of the invention may be operably linked to a promoter. The invention provides recombinant vector (e.g., an expression vector) expressing the CCX CKR polypeptides of the invention. In one aspect, the invention provides a polynucleotide having sequence encoding a polypeptide that has an activity (e.g., a chemokine binding activity) of a CCX CKR polypeptide and which is (a) a polynucleotide having the sequence of SEQ ID NO:1 or SEQ ID NO:3 ~~SEQ ID NO:3~~; or (b) a polynucleotide which hybridizes under stringent conditions to (a); or (c) a polynucleotide sequence which is degenerate as a result of the genetic code to the sequences defined in (a) or (b).

Paragraph beginning at line 3 of page 5 has been amended as follows:

Figure 1 shows the nucleotide sequence for a human CCX CKR (SEQ ID NO:1) ~~(SEQ ID NO:1)~~ and the predicted amino acid sequence of the human CCX CKR polypeptide (SEQ ID NOS:2 and 12-14) ~~(SEQ ID NO:2)~~.

Paragraph beginning at line 7 of page 5 has been amended as follows:

Figure 2 shows the CCX CKR sequence aligned with those of other chemokine receptors, the expression pattern of CCX CKR RNA, and generation of a stable cell line expressing CCX CKR. Figure 2A shows sequence homology of the CCX CKR coding region (SEQ ID NO:2) with other chemokine receptors (SEQ ID NOS:6-9). Figure 2B shows cells and tissues expressing CCX CKR RNA, as analyzed by RT-PCR of cytoplasmic RNA from cultured primary cells and whole tissues from various organs as indicated. Figure 2C shows a population of transfected HEK-293 cells stably expressing CCX CKR protein containing an N-terminal Flag epitope, comparing intensity of anti-Flag mAb staining relative to wild type HEK293 cells.

Paragraph beginning at line 13 of page 6 has been amended as follows:

Figure 5 shows DNA sequence 5' to the translation start site of the CCX CKR gene (SEQ ID NOS:10 and 11), as determined from a genomic clone.